Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3519ea242d97a904badff9271f63de45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a8e20137e10efebd66f7b326dc42151 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-61 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
filingDate |
2017-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b8cf3623ada751c6dfe38771c565bed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02df93203ba2ba83b3246e3b0b8159b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b16d90fcee17258806b3dea9e41fc0e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12d1b809eb336ba17ff81502a6a2dedf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df6ad17cb999849a87b4ea0f409bf6fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2e1a507beba0151b4bc73d66445dc8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbbce06881a78edbd2e4eefe4839953e |
publicationDate |
2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
TW-201925237-A |
titleOfInvention |
Use and kit of human growth hormone fusion protein GX-H9 |
abstract |
A use of human growth hormone fusion protein (GX-H9) is used to prepare a medicine for treating growth hormone deficiency. The human growth hormone fusion protein is a fusion protein of human growth hormone (hGH) and hybrid Fc, wherein the human growth hormone fusion protein is administered once every two weeks at a dose of 1.0 to 3.0 mg per kilogram body weight of a patient. |
priorityDate |
2016-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |